China Approves World's First Commercial Brain Implant, Beating Neuralink to Market

A Historic First in Brain-Computer Interfaces

China has made history by approving the world's first invasive brain-computer interface device for commercial medical use. The National Medical Products Administration granted marketing approval to Shanghai-based Neuracle Medical Technology for its NEO Brain-Computer Interface System, a device designed to restore hand-grasping ability in patients with quadriplegia caused by cervical spinal cord injuries.

How the NEO System Works

The system uses a coin-sized wireless implant placed on the brain's outer surface through a minimally invasive procedure that does not penetrate brain tissue. Surgeons mill a small groove in the skull and position electrodes outside the dura mater, the protective membrane surrounding the brain, to read neural signals. When a patient thinks about grasping an object, the device decodes those brain signals in real time and transmits commands to a pneumatic glove that enables the hand to grip. The device has been tested in thirty-six patients, with clinical trials showing improvements in hand-grasping ability and daily functioning.

A Strategic National Priority

The approval comes as Beijing has elevated brain-computer interface technology to a national strategic priority. BCI was included for the first time in China's government work report as one of the country's industries of the future, and policy planning for the upcoming fifteenth Five-Year Plan highlights the sector as a potential engine of economic growth. In August twenty twenty-five, China's industry ministry and six other agencies released a national roadmap targeting major technical milestones by twenty twenty-seven.

The Global Race Intensifies

The milestone sharpens competition with the United States, where Elon Musk's Neuralink has been conducting human trials since twenty twenty-four but has not yet received commercial approval from the Food and Drug Administration. Neuralink plans to begin high-volume production in twenty twenty-six and expand trials internationally, but full commercial FDA approval is not expected until around twenty twenty-eight. Meanwhile, shares of BCI-related companies rose on mainland Chinese exchanges, with some surging more than ten percent. China's BCI market is projected to grow to around eight hundred million dollars by twenty twenty-seven.